Choline

Choline

SCHEMBL6706932

CC(=O)C(=O)[O-].C[N+](C)(C)CCO

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2

The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
LMNA P02545 1/20 0.57
KMT2A Q03164 1/20 0.57
CYP3A4 P08684 1/20 0.57
SLC5A7 Q9GZV3 1/20 0.57
CA4 P22748 2/20 0.50
GALR3 O60755 2/20 0.43
ACHE P22303 1/20 0.41
CHRM5 P08912 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39
PGR P06401 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
HTR1A P08908 1/20 0.39
CHRNB2 P17787 1/20 0.39
TBXA2R P21731 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Choline SCHEMBL31575663 0.90 LMNA (0.63) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL1052170 0.90 LMNA (0.63) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL316506 0.90 LMNA (0.63) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL30113090 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL3345299 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL28408316 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL3789465 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL28990098 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL3789470 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7
Choline SCHEMBL3789466 0.87 LMNA (0.60) MEN1LMNAKMT2ACYP3A4SLC5A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8187489-B1 Biodegradable ionic liquids for aircraft deicing THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-05-29 US claimed
CN-100355737-C Pyruvic acid type ionic liquid and its preparing method UNIV EAST CHINA NORMAL (CN) 2007-12-19 CN claimed
CN-1821228-A Pyruvic acid type ionic liquid and its preparing method UNIV EAST CHINA NORMAL (CN) 2006-08-23 CN claimed
US-20040006139-A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof DEGUSSA AG (DE) 2004-01-08 US claimed
EP-2994161-A1 PROBIOTIC PREVENTION AND TREATMENT OF COLON CANCER California Institute of Technology (US) 2016-03-16 EP disclosed
WO-2014182966-A1 PROBIOTIC PREVENTION AND TREATMENT OF COLON CANCER CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-11-13 WO disclosed
US-8187489-B1 Biodegradable ionic liquids for aircraft deicing THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-05-29 US disclosed
CN-100355737-C Pyruvic acid type ionic liquid and its preparing method UNIV EAST CHINA NORMAL (CN) 2007-12-19 CN disclosed
CN-1821228-A Pyruvic acid type ionic liquid and its preparing method UNIV EAST CHINA NORMAL (CN) 2006-08-23 CN disclosed
US-20040006139-A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof DEGUSSA AG (DE) 2004-01-08 US disclosed
US-20040006139-A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof DEGUSSA AG (DE) 2004-01-08 US disclosed
US-20040006139-A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof DEGUSSA AG (DE) 2004-01-08 US disclosed
EP-1343490-A1 CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF Degussa AG (DE) 2003-09-17 EP disclosed
EP-1343490-A1 CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF Degussa AG (DE) 2003-09-17 EP disclosed
WO-2002051398-A1 CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF DEGUSSA AG (DE) 2002-07-04 WO disclosed
WO-2002051398-A1 CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF DEGUSSA AG (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006139-A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof PDK1, PC, PDK4 MEN1 1006/4885LMNA 1770/4885KMT2A 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.